<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00069121</url>
  </required_header>
  <id_info>
    <org_study_id>NO16968</org_study_id>
    <nct_id>NCT00069121</nct_id>
    <nct_alias>NCT00080691</nct_alias>
  </id_info>
  <brief_title>A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer</brief_title>
  <official_title>An Open-Label Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) (&quot;XELOX&quot;) Versus Fluorouracil/Leucovorin as Adjuvant Therapy for Patients Who Have Undergone Surgery for Colon Carcinoma, AJCC/UICC Stage III (Dukes Stage C)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This 2 arm study will compare the efficacy and safety of intermittent oral Xeloda plus
      Eloxatin (oxaliplatin) with that of fluorouracil/leucovorin in patients who have had surgery
      for colon cancer and no previous chemotherapy. Patients will be randomized to receive either
      1) XELOX (Xeloda 1000mg/m2 po bid on days 1-15 + oxaliplatin) in 3 week cycles or
      2)5-fluorouracil + leucovorin in 4 or 8 week cycles. The anticipated time on study treatment
      is until disease progression and the target sample size is 500+ individuals.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 18, 2003</start_date>
  <completion_date type="Actual">April 21, 2011</completion_date>
  <primary_completion_date type="Actual">April 21, 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-Free Survival (DFS) [Number of Events]</measure>
    <time_frame>Time from randomization date to date of first DFS event/date last known to be event-free. Median observation time for DFS was 74 months (range: 0-95 months).</time_frame>
    <description>Determination of an event was based on tumor assessments and survival follow-up assessments. A disease-free survival (DFS) event was defined as any recurrence of the original colon cancer or appearance of a new colon or rectal cancer (proven by cytology or histology, when possible) or death due to any cause, whichever was earliest. Participants who had not had any such event at the time of data analysis were censored at the last date they were known to be event-free. Participants with no tumor assessments after baseline were censored at Day 1. An isolated event of increased CEA, or unexplained clinical deterioration were not considered to be evidence of relapse without support of other objective measurements. The date of relapse was defined as the date of the definitive assessment by objective measurements.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease-Free Survival (DFS) [Time to Event]</measure>
    <time_frame>Time from randomization date to date of first DFS event/date last known to be event-free. Median observation time for DFS was 74 months (range: 0-95 months).</time_frame>
    <description>Determination of an event was based on tumor assessments and survival follow-up assessments. A disease-free survival (DFS) event was defined as any recurrence of the original colon cancer or appearance of a new colon or rectal cancer (proven by cytology or histology, when possible) or death due to any cause, whichever was earliest. Participants who had not had any such event at the time of data analysis were censored at the last date they were known to be event-free. Participants with no tumor assessments after baseline were censored at Day 1. An isolated event of increased CEA, or unexplained clinical deterioration were not considered to be evidence of relapse without support of other objective measurements. The date of relapse was defined as the date of the definitive assessment by objective measurements. The median was estimated by the Kaplan-Meier method. The full range values include censored observations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relapse-Free Survival (RFS) [Number of Events]</measure>
    <time_frame>Time from randomization date to date of first RFS event/date last known to be event-free. Median observation time for RFS was 74 months (range: 0-95 months).</time_frame>
    <description>A relapse-free survival (RFS) event included recurrence of the original colon cancer, development of a new colon or rectal cancer, and deaths related to any of the following: treatment, recurrence of the original colon cancer, or development of a new colon or rectal cancer. Participants who had not had any such event at the time of data analysis were censored at the last date they were known to be event-free. Participants whose cause of death was unrelated to treatment or disease recurrence were censored at the time of the last tumor assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-Free Survival (RFS) [Time to Event]</measure>
    <time_frame>Time from randomization date to date of first RFS event/date last known to be event-free. Median observation time for RFS was 74 months (range: 0-95 months).</time_frame>
    <description>A relapse-free survival (RFS) event included recurrence of the original colon cancer, development of a new colon or rectal cancer, and deaths related to any of the following: treatment, recurrence of the original colon cancer, or development of a new colon or rectal cancer. Participants who had not had any such event at the time of data analysis were censored at the last date they were known to be event-free. Participants whose cause of death was unrelated to treatment or disease recurrence were censored at the time of the last tumor assessment. The median was estimated by the Kaplan-Meier method. The full range values include censored observations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival [Number of Events]</measure>
    <time_frame>Time from randomization date to date of death/date last known to be alive. Median observation time was 83 months (range: 0-95 months).</time_frame>
    <description>Overall survival was measured as the time from randomization to the date of death, irrespective of the cause of death. Participants who were not reported as having died at the time of the analysis were censored using the date they were last known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival [Time to Event]</measure>
    <time_frame>Time from randomization date to date of death/date last known to be alive. Median observation time was 83 months (range: 0-95 months).</time_frame>
    <description>Overall survival was measured as the time from randomization to the date of death, irrespective of the cause of death. Participants who were not reported as having died at the time of the analysis were censored using the date they were last known to be alive. The median was estimated by the Kaplan-Meier method. The full range values include censored observations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With at Least One Adverse Event by Most Severe Intensity</measure>
    <time_frame>From time of very first drug intake to 28 days after very last drug intake (median [full range] duration of study treatment per arm: 5-FU/LV MAYO CLINIC: 145 [4-208] days; 5-FU/LV ROSWELL PARK: 204 [1-239] days; XELOX: 163 [1-275] days).</time_frame>
    <description>The intensity of all adverse events (AEs) was categorized according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) (version 3.0) grading system. If an AE had occurred which was not contained in the NCI-CTC, a four-point scale (mild, moderate, severe, life-threatening) was used. The terms &quot;severe&quot; and &quot;serious&quot; are not synonymous and are independently assessed for each AE. Only the most severe intensity was counted for multiple occurrences of an AE in one individual. See the AEs results table for details.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1886</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>5-Fluorouracil/Leucovorin (5-FU/LV)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants were given one of two regimens (each participating center prespecified which regimen they would use for all patients at that center): i) Mayo Clinic regimen group: LV 20 mg/m^2 IV bolus injection + 5-FU 425 mg/m^2 IV bolus injection daily on Days 1-5 of a four-week cycle, for a total of six cycles (24 weeks), or; ii) Roswell Park regimen group: LV 500 mg/m^2 by two-hour IV infusion + 5-FU 500 mg/m^2 IV bolus injection one hour after the start of the LV infusion on Day 1 of Weeks 1 to 6 of each eight-week cycle, for a total of four cycles (32 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Capecitabine in Combination with Oxaliplatin (XELOX)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capecitabine was administered as an oral twice daily outpatient intermittent treatment (3-week cycles consisting of two weeks of treatment followed by one week without treatment) combined with intravenous (IV) oxaliplatin on Day 1 of each cycle. Capecitabine was administered orally at a dose of 1000 mg/m^2 twice-daily (equivalent to a total daily dose of 2000 mg/m^2) with the first dose given during the evening of Day 1 and last dose given during the morning of Day 15. Oxaliplatin was administered as a 130 mg/m^2 IV infusion over two hours on Day 1 of each cycle. The XELOX combination was administered for a total of eight cycles (24 weeks).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>1000 milligrams per square metre of body surface area (mg/m^2) orally twice daily on days 1-15 of each 3-week cycle.</description>
    <arm_group_label>Capecitabine in Combination with Oxaliplatin (XELOX)</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>130 mg/m^2 intravenous (IV) infusion over two hours on Day 1 of each 3-week cycle.</description>
    <arm_group_label>Capecitabine in Combination with Oxaliplatin (XELOX)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin (LV)</intervention_name>
    <description>Administered by one of two regimens, as specified in the arm description.</description>
    <arm_group_label>5-Fluorouracil/Leucovorin (5-FU/LV)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Fluorouracil (5-FU)</intervention_name>
    <description>Administered by one of two regimens, as specified in the arm description.</description>
    <arm_group_label>5-Fluorouracil/Leucovorin (5-FU/LV)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed colon carcinoma, AJCC/UICC Stage III (Dukes stage C)

          -  Complete tumor resection; Patients operated with curative intent and with no
             macroscopic or microscopic evidence for remaining tumor who can be randomized to
             either treatment arm within 8 weeks after surgery. As this is an adjuvant trial
             patients should never have had any evidence of metastatic disease (including presence
             of tumor cells in the ascites).

          -  Have a life expectancy of at least 5 years

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Sexually active males and females (of childbearing potential) unwilling to practice
             contraception during the study

          -  Previous cytotoxic chemotherapy, radiotherapy or immunotherapy, for the currently
             treated colon cancer

          -  Patients who have not completely recovered from surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Cancer Center At Providence Park</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Hematology Oncology Medical Group Inc.</name>
      <address>
        <city>Alhambra</city>
        <state>California</state>
        <zip>91801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Blood/Cancer Ctr</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia K. Crossen Cancer Center</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Shores Medical Group</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Valley Hematology Oncology The Thomas and Dorothy Leavey Cancer Center</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91325</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ventura County Hematology-Oncology Specialists</name>
      <address>
        <city>Oxnard</city>
        <state>California</state>
        <zip>93030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilshire Oncology Medical Group</name>
      <address>
        <city>Pomona</city>
        <state>California</state>
        <zip>91767</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sutter Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Cancer Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente San Diego; Hepatology Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92154</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Barbara Hematology Oncology Medical Group, Inc.</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Diego Cancer Center'S Medical Group</name>
      <address>
        <city>Vista</city>
        <state>California</state>
        <zip>92083</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovative clinical research institute/American institute of research</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Health Science Center; Biomedical Research Bldg. Room 511</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Associates</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80528</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology P.C.</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown Uni Medical Center; Lombardi Cancer Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lakeland Regional Cancer Center</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33804-1057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uni of Miami School of Medicine; Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Cancer Specialists</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30341</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois Cancer Care</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hope Center</name>
      <address>
        <city>Terre Haute</city>
        <state>Indiana</state>
        <zip>47802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Cancer Inst.</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Park Nicollet Clinic Cancer Center</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Joseph Oncology</name>
      <address>
        <city>Saint Joseph</city>
        <state>Missouri</state>
        <zip>64507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Consultants, Inc.</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology-Oncology Centers of the Northern Rockies</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Falls Clinic</name>
      <address>
        <city>Great Falls</city>
        <state>Montana</state>
        <zip>59405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Va Medical Center</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nh Oncology Hematology, Pa</name>
      <address>
        <city>Hooksett</city>
        <state>New Hampshire</state>
        <zip>03106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morristown Medical Center;Hematology-Oncology Assoc</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Overlook Oncology Center; Summit Medical Group</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <zip>07901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Mexico Oncology Hematology Consultants</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent'S Hospital; Comprehensive Care Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presbyterian Healthcare; Cancer Research Dept</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28233-3549</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moses Cone Reg Cancer Ctr</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Oncology Specialists, PA - Hickory</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology-Hematology of Lehigh Valley, Pc</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Associates</name>
      <address>
        <city>Kingston</city>
        <state>Pennsylvania</state>
        <zip>18704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the Uni of Pennsylvania; Section of Hematology/Oncology</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase-Temple Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uni of Pittsburgh Cancer Inst. ; Oncology</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Clinic</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US Oncology</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77380</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermountain Hematology &amp; Oncology</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internal Medicine Associates of Yakima Inc.</name>
      <address>
        <city>Yakima</city>
        <state>Washington</state>
        <zip>98902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNI OF WISCONSIN SCHOOL OF MEDICINE; GI Oncology Research Group, Paul P Carbone Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital; Medical Oncology</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Port Macquarie Base Hospital; Oncology</name>
      <address>
        <city>Port Macquarie</city>
        <state>New South Wales</state>
        <zip>2444</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Medical Day Care; Clinical Trials Unit</name>
      <address>
        <city>Wollongong</city>
        <state>New South Wales</state>
        <zip>2500</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital; Medical Oncology</name>
      <address>
        <city>Woodville South</city>
        <state>South Australia</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Box Hill Hospital; Oncology</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Footscray Hospital</name>
      <address>
        <city>Footscray</city>
        <state>Victoria</state>
        <zip>3011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St John of God Hospital; Medical Oncology</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires St-Luc</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GHdC Site Notre Dame</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Groeninge</name>
      <address>
        <city>Kortrijk</city>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Baleia; Serviço de Oncologia Clínica</name>
      <address>
        <city>Belo Horizonte</city>
        <state>MG</state>
        <zip>30285-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Amaral Carvalho</name>
      <address>
        <city>Jau</city>
        <state>SP</state>
        <zip>17210-120</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas - FMUSP; Gastroenterologia</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre; Dept of Medicine</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute ; Dept of Medical Oncology</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bcca - Cancer Center Southern Interior</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 5L3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bcca-Fraser Valley Cancer Centre</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3V 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bcca - Vancouver Island Cancer Centre; Oncology</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8R 6V5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Boniface General Hospital</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R2H 2A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. H. Bliss Murphy Cancer Centre; Oncology</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Centre; Oncology</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences - Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Credit Valley Hospital/Carlo Fidani Peel Regional Cancer Centre</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5M 2N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lakeridge Health Oshawa; Oncology</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1G 2B9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital Cancer Centre; Oncology</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Humber River Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M3M 0B2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Science Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network; Princess Margaret Hospital; Medical Oncology Dept</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cite de La Sante de Laval; Hemato-Oncologie</name>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <zip>H7M 3L9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hotel Dieu de Levis; Oncology</name>
      <address>
        <city>Levis</city>
        <state>Quebec</state>
        <zip>G6V 3Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Maisonneuve- Rosemont; Oncology</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chum Campus Notre Dame</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Du Sacre Coeur de Montreal; Pneumologie</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chuq - Hopital Hotel Dieu de Quebec; Oncology</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Sciences.</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital, Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Zhejiang University College</name>
      <address>
        <city>Hangzhou</city>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The 1st Affiliated Hospital of Nanchang Unversity</name>
      <address>
        <city>Nanchang</city>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangsu Cancer Hospital</name>
      <address>
        <city>Nanjing</city>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shandong Cancer Hospital; Oncology</name>
      <address>
        <city>Shandong</city>
        <zip>250117</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai City</city>
        <zip>200120</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Jiao Tong University School of Medicine (SJTUSM) - Ruijin Hospital (GuangCi Hospital)</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <zip>200092</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Cancer Hospital</name>
      <address>
        <city>Tianjin</city>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tongji Hosp, Tongji Med. Col, Huazhong Univ. of Sci. &amp; Tech</name>
      <address>
        <city>Wuhan</city>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital; Dept of Oncology</name>
      <address>
        <city>Tampere</city>
        <zip>33520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Turku Uni Central Hospital; Oncology Clinics</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Louis Pasteur; Medecine B</name>
      <address>
        <city>Colmar</city>
        <zip>68024</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Claude Huriez; Medecine Interne Oncologie</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes; Oncologie Medicale</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Civil; Hematologie Oncologie</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis für Interdisziplinäre Onkologie und Hämatologie GbR</name>
      <address>
        <city>Freiburg</city>
        <zip>79110</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Halle; Klinik u.Poliklinik fuer Innere Medizin IV</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Magdeburg gemeinnützige GmbH; Klinik Haematologie und Onkologie</name>
      <address>
        <city>Magdeburg</city>
        <zip>39130</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Mutterhaus der Borromaeerinnen gGmbH; Haematologie/Onkologie</name>
      <address>
        <city>Trier</city>
        <zip>54290</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelismos Hospital; Medical Oncology</name>
      <address>
        <city>Athens</city>
        <zip>10676</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Per. Gen. Hospital Ippokrateion; Oncology Dept.</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ General Hosp Heraklion; Medical Oncology</name>
      <address>
        <city>Heraklion</city>
        <zip>711 10</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Patras Medical Oncology</name>
      <address>
        <city>Patras</city>
        <zip>265 04</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Theagenio Anticancer Hospital; 3Rd Oncology Clinic</name>
      <address>
        <city>Thessaloniki</city>
        <zip>546 39</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Theageneio Anticancer Hospital; Gastroenterology</name>
      <address>
        <city>Thessaloniki</city>
        <zip>56439</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital; Surgery</name>
      <address>
        <city>Hong Kong</city>
        <zip>852</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ogyi, Orszagos Gyogyszereszeti Intezet</name>
      <address>
        <city>Budapest</city>
        <zip>1051</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fovarosi Szent Laszlo Korhaz-Rendelointezet; Onkologiai Osztaly X</name>
      <address>
        <city>Budapest</city>
        <zip>1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orszagos Onkologial Intezet; Onkologiai Osztaly X</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szegedi Tudomanyegyetem, AOK, Szent-Gyorgyi Albert Klinikai Kozpont, Onkoterapias Klinika</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Uni Hospital; Deparment of Medical Oncology</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. James Hospital; Oncology</name>
      <address>
        <city>Dublin</city>
        <zip>8</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galway Uni Hospital; Oncology Dept</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soroka Medical Center; Oncology Dept</name>
      <address>
        <city>Beer Sheva</city>
        <zip>8410100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center; Oncology</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center; Oncology Dept</name>
      <address>
        <city>Jerusalem</city>
        <zip>9103102</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Ein Karem Hospital; Oncology Dept</name>
      <address>
        <city>Jerusalem</city>
        <zip>9112000</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meir Medical Center; Oncology</name>
      <address>
        <city>Kfar-Saba</city>
        <zip>4428164</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nahariya Hospital; Oncology</name>
      <address>
        <city>Nahariya</city>
        <zip>22100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center; Oncology Dept</name>
      <address>
        <city>Petach Tikva</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Golda Hasharon Medical Center; Oncology</name>
      <address>
        <city>Petach Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center; Oncology Dept</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52620-00</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaplan Medical Center; Oncology Inst.</name>
      <address>
        <city>Rehovot</city>
        <zip>7610001</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sourasky / Ichilov Hospital; Oncology Department</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239-06</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assaf Harofeh; Oncology</name>
      <address>
        <city>Zerifin</city>
        <zip>6093000</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Cervesi di Cattolica; ONCOLOGIA</name>
      <address>
        <city>Cattolica</city>
        <state>Emilia-Romagna</state>
        <zip>47841</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Regionale Di Parma; Divisione Di Oncologia Medica</name>
      <address>
        <city>Parma</city>
        <state>Emilia-Romagna</state>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Degli Infermi; Divisione Di Oncologia</name>
      <address>
        <city>Rimini</city>
        <state>Emilia-Romagna</state>
        <zip>47900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Dipartimento Interaziendale Di Oncologia</name>
      <address>
        <city>Udine</city>
        <state>Friuli-Venezia Giulia</state>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az. Osp. Uni Ria San Martino; Cliniche Uni Rie Convenzionate U.O. Oncologia Medical</name>
      <address>
        <city>Genova</city>
        <state>Liguria</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asst Papa Giovanni XXIII; Oncologia Medica</name>
      <address>
        <city>Bergamo</city>
        <state>Lombardia</state>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irccs Istituto Europeo Di Oncologia (IEO); Oncologia Medica</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Ospedali Riuniti Umberto I-G.M.Lancisi-G.Salesi Ancona;S.O.D. MED.Interna-Clinica Oncologica</name>
      <address>
        <city>Ancona</city>
        <state>Marche</state>
        <zip>60121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile; Oncologia Medica</name>
      <address>
        <city>Sassari</city>
        <state>Sardegna</state>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile; Unita Operativa Di Oncologia Medica</name>
      <address>
        <city>Livorno</city>
        <state>Toscana</state>
        <zip>57100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Usl 7; Dept. Oncologico</name>
      <address>
        <city>Poggibonsi</city>
        <state>Toscana</state>
        <zip>53036</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National Uni Hospital; Dept. of Internal Medicine/Hematology/Oncology</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei Medical Center; Dept. of Medicine , Division of Hemato-Oncology</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanyang Uni Hospital; Dept. of Internal Medicine , Section of Hemato-Oncology</name>
      <address>
        <city>Seoul</city>
        <zip>133-792</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Centre; Division of Hematology/Oncology</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center, Uni Ulsan Collegemedicine; Dept.Internal Medicine / Divisionhematology/Oncology</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Estatal de Cancerología</name>
      <address>
        <city>Chihuahua</city>
        <zip>31000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Christus Muguerza Del Parque; Centro de Rehabilitacion</name>
      <address>
        <city>Chihuahua</city>
        <zip>31000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica de Especialidades # 30 Dr. Humberto Torres Sangines; Oncology</name>
      <address>
        <city>Mexicali</city>
        <zip>21100</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional De Ciencias Medicas Y Nutricion; Nefrology</name>
      <address>
        <city>Mexico City</city>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland city hospital; Auckland Regional Cancer Centre and Blood Service</name>
      <address>
        <city>Auckland</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital; Dept of Oncology</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dunedin Hospital; Oncology - Haematology Clinical Practice Group</name>
      <address>
        <city>Dunedin</city>
        <zip>9016</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palmerston North Hospital; Regional Cancer Treatment Service</name>
      <address>
        <city>Palmerston North</city>
        <zip>4442</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellington Hospital; Regional Oncology Unit</name>
      <address>
        <city>Wellington</city>
        <zip>6002</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isthmian Medical Research Center, S.A.; Oncology</name>
      <address>
        <city>Panama City</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rydygiera Hospital; Chemotherapy</name>
      <address>
        <city>Krakow</city>
        <zip>31-826</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Specjalistyczny Im. M. Kopernika; Oddzial Chorob Rozrostowych</name>
      <address>
        <city>Lodz</city>
        <zip>93-509</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wielkopolskie Centrum Onkologii; Oddzial Chemioterapii</name>
      <address>
        <city>Poznan</city>
        <zip>61-866</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zachodniopomorskie Centrum Onkologii, Osrodek Innowacyjnosci, Rozwoju i Badan Klinicznych</name>
      <address>
        <city>Szczecin</city>
        <zip>71-730</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii - Inst.Im. Marii Sklodowskiej-Curie; Klinika Nowotworow Jelita Grubego</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lubuski Osrodek Onkologii, Szpital Wojewodzki; Oddzial Onkologii</name>
      <address>
        <city>Zielona Gora</city>
        <zip>65-046</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Jose Joaquim Fernandes; Unidade de Oncologia Medica</name>
      <address>
        <city>Beja</city>
        <zip>7801-849</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Santa Maria; Servico de Oncologia Medica</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IPO do Porto; Servico de Oncologia Medica</name>
      <address>
        <city>Porto</city>
        <zip>4200-072</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>N.N.Burdenko Main Military Clinical Hospital; Chemotherapy</name>
      <address>
        <city>Moscow</city>
        <zip>105229</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blokhin Cancer Research Center; Combined Treatment</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Petrov Research Inst. of Oncology; Dept of Bio-Therapy &amp; Transplantation of Bone Marrow</name>
      <address>
        <city>St Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg City Clinical Oncological Dispensary; Colorectal (Department 4)</name>
      <address>
        <city>St Petersburg</city>
        <zip>198255</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National University Hospital; National University Cancer Institute, Singapore (NCIS)</name>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre; Medical Oncology</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Panorama Medical Clinic; Oncology Unit</name>
      <address>
        <city>Cape Town</city>
        <zip>7500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopelands Cancer Centre; Oncology</name>
      <address>
        <city>Durban</city>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopelands Cancer Centre ST. ANNES HOSPITAL; DEPT. OF ONCOLOGY</name>
      <address>
        <city>Pietermaritzburg</city>
        <zip>3201</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Little Company of Mary Hospital; Mary Potter Oncology Centre</name>
      <address>
        <city>Pretoria</city>
        <zip>0001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandton Oncology Medical Group</name>
      <address>
        <city>Sandton</city>
        <zip>2196</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Elche; Servicio de Oncologia</name>
      <address>
        <city>Elche</city>
        <state>Alicante</state>
        <zip>03203</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marques de Valdecilla; Servicio de Oncologia</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofia; Servicio de Oncologia</name>
      <address>
        <city>Córdoba</city>
        <state>Cordoba</state>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Son Espases</name>
      <address>
        <city>Palma De Mallorca</city>
        <state>Islas Baleares</state>
        <zip>07014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Severo Ochoa; Servicio de Oncologia</name>
      <address>
        <city>Leganes</city>
        <state>Madrid</state>
        <zip>28911</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro; Servicio de Oncologia</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Cruces; Servicio de Oncologia</name>
      <address>
        <city>Bilbao</city>
        <state>Vizcaya</state>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Univ Vall d'Hebron; Servicio de Oncologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic i Provincial; Servicio de Hematología y Oncología</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Duran i Reynals; Oncologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Jaen-Hospital Universitario Medico Quirurgico; Servicio de Oncologia</name>
      <address>
        <city>Jaen</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de la Princesa; Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañon; Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Clínico San Carlos; Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre; Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz; Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario Carlos Haya; Servicio de Oncologia</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano Oncologia; Oncologia Medica</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario la Fe; Servicio de Oncologia</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital Basel; Onkologie</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Koo Foundation Sun Yat-Sen Cancer Center; Hemato-Oncology</name>
      <address>
        <city>Taipei City</city>
        <zip>11259</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mackay Memorial Hospital; Department of Surgery, Division of Colon and Rectal Surgery</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Medical Foundation - Linkou; Colo-rectal Surgery</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bumrungrad Hospital Foundation; Horizon Centre</name>
      <address>
        <city>Bangkok</city>
        <zip>10110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pramongkutklao Hospital; Medicine - Medical Oncology Unit</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ramathibodi Hospital; Dept of Med.-Div. of Med. Onc</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Srinagarind Hospital; Medical Oncology Unit</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aberdeen Royal Infirmary; Medical Oncology Dept</name>
      <address>
        <city>Aberdeen</city>
        <zip>AB25 2ZN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Sussex County Hospital; the Sussex Cancer Centre</name>
      <address>
        <city>Brighton</city>
        <zip>BN2 5BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Suffolk Hospital Nhs Trust; Gi Corridor</name>
      <address>
        <city>Bury St Edmunds</city>
        <zip>IP33 2QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrooke'S Hospital; Univ.Dept.&amp; Mrc Unit of Clin.Oncology &amp; Radiotherapeutics</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 2QH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derbyshire Royal Infirmary; Dept of Oncology</name>
      <address>
        <city>Derby</city>
        <zip>DE1 2QY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cruk Clinical Trials Unit; Level 0 Beatson West Of Scotland Cancer Ctr</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Surrey County Hospital; St. Lukes Cancer Centre</name>
      <address>
        <city>Guildford</city>
        <zip>GU2 7XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St James Institute of Oncology</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary; Dept. of Medical Oncology</name>
      <address>
        <city>Leicester</city>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Thomas Hospital; Oncology Dept</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Nhs Trust; Consultant Cancer Physician</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hammersmith Hospital; Mrc Clinical Science Centre</name>
      <address>
        <city>London</city>
        <zip>W12 OHS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charing Cross Hospital; Medical Oncology.</name>
      <address>
        <city>London</city>
        <zip>W6 8RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maidstone Hospital</name>
      <address>
        <city>Maidstone</city>
        <zip>ME16 9QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christie Hospital; Breast Cancer Research Office</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4QL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James Cook Uni Hospital</name>
      <address>
        <city>Middlesborough</city>
        <zip>TS4 3BW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Centre for Cancer Care;Oncology</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Vernon Hospital; Centre For Cancer Treatment</name>
      <address>
        <city>Northwood</city>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham City Hospital; Oncology</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital; Plymouth Oncology Centre</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Wales Cancer Treatment Centre, Glan Clwyd Hospital</name>
      <address>
        <city>Rhyl</city>
        <zip>LL18 5UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salisbury District General Hospital; Medical Oncology Dept</name>
      <address>
        <city>Salisbury</city>
        <zip>SP2 8BJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital; Somers Cancer Research Building</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital; Dept of Medical Oncology</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>China</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>New Zealand</country>
    <country>Panama</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 15, 2003</study_first_submitted>
  <study_first_submitted_qc>September 17, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2003</study_first_posted>
  <results_first_submitted>March 31, 2011</results_first_submitted>
  <results_first_submitted_qc>July 5, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 29, 2011</results_first_posted>
  <last_update_submitted>February 14, 2020</last_update_submitted>
  <last_update_submitted_qc>February 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>5-FU/LV</title>
          <description>Given by one of two regimens. • Mayo Clinic regimen group: LV 20 mg/m^2 IV bolus injection + 5-FU 425 mg/m^2 IV bolus injection daily on Days 1-5 of a four-week cycle, for a total of six cycles (24 weeks), or • Roswell Park regimen group: LV 500 mg/m^2 by two-hour IV infusion + 5-FU 500 mg/m^2 IV bolus injection one hour after the start of the LV infusion on Day 1 of Weeks 1 to 6 of each eight-week cycle, for a total of four cycles (32 weeks)</description>
        </group>
        <group group_id="P2">
          <title>XELOX</title>
          <description>Capecitabine administered as an oral twice daily outpatient intermittent treatment (3-week cycles consisting of two weeks of treatment followed by one week without treatment) combined with intravenous (IV) oxaliplatin on Day 1 of each cycle. Capecitabine was administered orally at a dose of 1000 mg/m^2 twice-daily (equivalent to a total daily dose of 2000 mg/m^2) with the first dose given during the evening of Day 1 and last dose given during the morning of Day 15. Oxaliplatin was administered as a 130 mg/m^2 IV infusion over two hours on Day 1 of each cycle. The XELOX combination was administered for a total of eight cycles (24 weeks)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="942"/>
                <participants group_id="P2" count="944"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="926">Safety Population</participants>
                <participants group_id="P2" count="938">Safety Population</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="575">total includes Completed and Alive in follow-up</participants>
                <participants group_id="P2" count="619">total includes Completed and Alive in follow-up</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="367"/>
                <participants group_id="P2" count="325"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="286"/>
                <participants group_id="P2" count="242"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="63"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>5-FU/LV</title>
          <description>Given by one of two regimens. • Mayo Clinic regimen group: LV 20 mg/m^2 IV bolus injection + 5-FU 425 mg/m^2 IV bolus injection daily on Days 1-5 of a four-week cycle, for a total of six cycles (24 weeks), or • Roswell Park regimen group: LV 500 mg/m^2 by two-hour IV infusion + 5-FU 500 mg/m^2 IV bolus injection one hour after the start of the LV infusion on Day 1 of Weeks 1 to 6 of each eight-week cycle, for a total of four cycles (32 weeks)</description>
        </group>
        <group group_id="B2">
          <title>XELOX</title>
          <description>Capecitabine administered as an oral twice daily outpatient intermittent treatment (3-week cycles consisting of two weeks of treatment followed by one week without treatment) combined with intravenous (IV) oxaliplatin on Day 1 of each cycle. Capecitabine was administered orally at a dose of 1000 mg/m^2 twice-daily (equivalent to a total daily dose of 2000 mg/m^2) with the first dose given during the evening of Day 1 and last dose given during the morning of Day 15. Oxaliplatin was administered as a 130 mg/m^2 IV infusion over two hours on Day 1 of each cycle. The XELOX combination was administered for a total of eight cycles (24 weeks)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="942"/>
            <count group_id="B2" value="944"/>
            <count group_id="B3" value="1886"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.5" spread="10.76"/>
                    <measurement group_id="B2" value="59.8" spread="10.95"/>
                    <measurement group_id="B3" value="60.2" spread="10.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="442"/>
                    <measurement group_id="B2" value="431"/>
                    <measurement group_id="B3" value="873"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="500"/>
                    <measurement group_id="B2" value="513"/>
                    <measurement group_id="B3" value="1013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="442"/>
                    <measurement group_id="B2" value="431"/>
                    <measurement group_id="B3" value="873"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="500"/>
                    <measurement group_id="B2" value="513"/>
                    <measurement group_id="B3" value="1013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Disease-Free Survival (DFS) [Number of Events]</title>
        <description>Determination of an event was based on tumor assessments and survival follow-up assessments. A disease-free survival (DFS) event was defined as any recurrence of the original colon cancer or appearance of a new colon or rectal cancer (proven by cytology or histology, when possible) or death due to any cause, whichever was earliest. Participants who had not had any such event at the time of data analysis were censored at the last date they were known to be event-free. Participants with no tumor assessments after baseline were censored at Day 1. An isolated event of increased CEA, or unexplained clinical deterioration were not considered to be evidence of relapse without support of other objective measurements. The date of relapse was defined as the date of the definitive assessment by objective measurements.</description>
        <time_frame>Time from randomization date to date of first DFS event/date last known to be event-free. Median observation time for DFS was 74 months (range: 0-95 months).</time_frame>
        <population>Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>5-FU/LV</title>
            <description>Given by one of two regimens. • Mayo Clinic regimen group: LV 20 mg/m^2 IV bolus injection + 5-FU 425 mg/m^2 IV bolus injection daily on Days 1-5 of a four-week cycle, for a total of six cycles (24 weeks), or • Roswell Park regimen group: LV 500 mg/m^2 by two-hour IV infusion + 5-FU 500 mg/m^2 IV bolus injection one hour after the start of the LV infusion on Day 1 of Weeks 1 to 6 of each eight-week cycle, for a total of four cycles (32 weeks)</description>
          </group>
          <group group_id="O2">
            <title>XELOX</title>
            <description>Capecitabine administered as an oral twice daily outpatient intermittent treatment (3-week cycles consisting of two weeks of treatment followed by one week without treatment) combined with intravenous (IV) oxaliplatin on Day 1 of each cycle. Capecitabine was administered orally at a dose of 1000 mg/m^2 twice-daily (equivalent to a total daily dose of 2000 mg/m^2) with the first dose given during the evening of Day 1 and last dose given during the morning of Day 15. Oxaliplatin was administered as a 130 mg/m^2 IV infusion over two hours on Day 1 of each cycle. The XELOX combination was administered for a total of eight cycles (24 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Disease-Free Survival (DFS) [Number of Events]</title>
          <description>Determination of an event was based on tumor assessments and survival follow-up assessments. A disease-free survival (DFS) event was defined as any recurrence of the original colon cancer or appearance of a new colon or rectal cancer (proven by cytology or histology, when possible) or death due to any cause, whichever was earliest. Participants who had not had any such event at the time of data analysis were censored at the last date they were known to be event-free. Participants with no tumor assessments after baseline were censored at Day 1. An isolated event of increased CEA, or unexplained clinical deterioration were not considered to be evidence of relapse without support of other objective measurements. The date of relapse was defined as the date of the definitive assessment by objective measurements.</description>
          <population>Intent-to-Treat Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="942"/>
                <count group_id="O2" value="944"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients with Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="379"/>
                    <measurement group_id="O2" value="320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients without Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="563"/>
                    <measurement group_id="O2" value="624"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relapse-Free Survival (RFS) [Number of Events]</title>
        <description>A relapse-free survival (RFS) event included recurrence of the original colon cancer, development of a new colon or rectal cancer, and deaths related to any of the following: treatment, recurrence of the original colon cancer, or development of a new colon or rectal cancer. Participants who had not had any such event at the time of data analysis were censored at the last date they were known to be event-free. Participants whose cause of death was unrelated to treatment or disease recurrence were censored at the time of the last tumor assessment.</description>
        <time_frame>Time from randomization date to date of first RFS event/date last known to be event-free. Median observation time for RFS was 74 months (range: 0-95 months).</time_frame>
        <population>Intent-to-Treat (ITT) Population: all randomized participants who gave written informed consent. Participants in the ITT population were analyzed according to the treatment arm to which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>5-FU/LV</title>
            <description>Given by one of two regimens. • Mayo Clinic regimen group: LV 20 mg/m^2 IV bolus injection + 5-FU 425 mg/m^2 IV bolus injection daily on Days 1-5 of a four-week cycle, for a total of six cycles (24 weeks), or • Roswell Park regimen group: LV 500 mg/m^2 by two-hour IV infusion + 5-FU 500 mg/m^2 IV bolus injection one hour after the start of the LV infusion on Day 1 of Weeks 1 to 6 of each eight-week cycle, for a total of four cycles (32 weeks)</description>
          </group>
          <group group_id="O2">
            <title>XELOX</title>
            <description>Capecitabine administered as an oral twice daily outpatient intermittent treatment (3-week cycles consisting of two weeks of treatment followed by one week without treatment) combined with intravenous (IV) oxaliplatin on Day 1 of each cycle. Capecitabine was administered orally at a dose of 1000 mg/m^2 twice-daily (equivalent to a total daily dose of 2000 mg/m^2) with the first dose given during the evening of Day 1 and last dose given during the morning of Day 15. Oxaliplatin was administered as a 130 mg/m^2 IV infusion over two hours on Day 1 of each cycle. The XELOX combination was administered for a total of eight cycles (24 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Relapse-Free Survival (RFS) [Number of Events]</title>
          <description>A relapse-free survival (RFS) event included recurrence of the original colon cancer, development of a new colon or rectal cancer, and deaths related to any of the following: treatment, recurrence of the original colon cancer, or development of a new colon or rectal cancer. Participants who had not had any such event at the time of data analysis were censored at the last date they were known to be event-free. Participants whose cause of death was unrelated to treatment or disease recurrence were censored at the time of the last tumor assessment.</description>
          <population>Intent-to-Treat (ITT) Population: all randomized participants who gave written informed consent. Participants in the ITT population were analyzed according to the treatment arm to which they were randomized.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="942"/>
                <count group_id="O2" value="944"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients With Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="356"/>
                    <measurement group_id="O2" value="290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients Without Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="586"/>
                    <measurement group_id="O2" value="654"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Disease-Free Survival (DFS) [Time to Event]</title>
        <description>Determination of an event was based on tumor assessments and survival follow-up assessments. A disease-free survival (DFS) event was defined as any recurrence of the original colon cancer or appearance of a new colon or rectal cancer (proven by cytology or histology, when possible) or death due to any cause, whichever was earliest. Participants who had not had any such event at the time of data analysis were censored at the last date they were known to be event-free. Participants with no tumor assessments after baseline were censored at Day 1. An isolated event of increased CEA, or unexplained clinical deterioration were not considered to be evidence of relapse without support of other objective measurements. The date of relapse was defined as the date of the definitive assessment by objective measurements. The median was estimated by the Kaplan-Meier method. The full range values include censored observations.</description>
        <time_frame>Time from randomization date to date of first DFS event/date last known to be event-free. Median observation time for DFS was 74 months (range: 0-95 months).</time_frame>
        <population>Intent-to-Treat (ITT) Population: all randomized participants who gave written informed consent. Participants in the ITT population were analyzed according to the treatment arm to which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>5-FU/LV</title>
            <description>Given by one of two regimens. • Mayo Clinic regimen group: LV 20 mg/m^2 IV bolus injection + 5-FU 425 mg/m^2 IV bolus injection daily on Days 1-5 of a four-week cycle, for a total of six cycles (24 weeks), or • Roswell Park regimen group: LV 500 mg/m^2 by two-hour IV infusion + 5-FU 500 mg/m^2 IV bolus injection one hour after the start of the LV infusion on Day 1 of Weeks 1 to 6 of each eight-week cycle, for a total of four cycles (32 weeks)</description>
          </group>
          <group group_id="O2">
            <title>XELOX</title>
            <description>Capecitabine administered as an oral twice daily outpatient intermittent treatment (3-week cycles consisting of two weeks of treatment followed by one week without treatment) combined with intravenous (IV) oxaliplatin on Day 1 of each cycle. Capecitabine was administered orally at a dose of 1000 mg/m^2 twice-daily (equivalent to a total daily dose of 2000 mg/m^2) with the first dose given during the evening of Day 1 and last dose given during the morning of Day 15. Oxaliplatin was administered as a 130 mg/m^2 IV infusion over two hours on Day 1 of each cycle. The XELOX combination was administered for a total of eight cycles (24 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Disease-Free Survival (DFS) [Time to Event]</title>
          <description>Determination of an event was based on tumor assessments and survival follow-up assessments. A disease-free survival (DFS) event was defined as any recurrence of the original colon cancer or appearance of a new colon or rectal cancer (proven by cytology or histology, when possible) or death due to any cause, whichever was earliest. Participants who had not had any such event at the time of data analysis were censored at the last date they were known to be event-free. Participants with no tumor assessments after baseline were censored at Day 1. An isolated event of increased CEA, or unexplained clinical deterioration were not considered to be evidence of relapse without support of other objective measurements. The date of relapse was defined as the date of the definitive assessment by objective measurements. The median was estimated by the Kaplan-Meier method. The full range values include censored observations.</description>
          <population>Intent-to-Treat (ITT) Population: all randomized participants who gave written informed consent. Participants in the ITT population were analyzed according to the treatment arm to which they were randomized.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="942"/>
                <count group_id="O2" value="944"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="0" upper_limit="95">The median time for DFS was not reached in this adjuvant trial; however, due to a late event in the XELOX arm and an artificial drop in the Kaplan-Meier estimate, an artificial median estimate for the XELOX groups appears.</measurement>
                    <measurement group_id="O2" value="88.6" lower_limit="0" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0038</p_value>
            <p_value_desc>This test used a two-sided significance level of 5%.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>0.93</ci_upper_limit>
            <estimate_desc>The hazard ratio was calculated as XELOX versus 5-FU/LV arms.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relapse-Free Survival (RFS) [Time to Event]</title>
        <description>A relapse-free survival (RFS) event included recurrence of the original colon cancer, development of a new colon or rectal cancer, and deaths related to any of the following: treatment, recurrence of the original colon cancer, or development of a new colon or rectal cancer. Participants who had not had any such event at the time of data analysis were censored at the last date they were known to be event-free. Participants whose cause of death was unrelated to treatment or disease recurrence were censored at the time of the last tumor assessment. The median was estimated by the Kaplan-Meier method. The full range values include censored observations.</description>
        <time_frame>Time from randomization date to date of first RFS event/date last known to be event-free. Median observation time for RFS was 74 months (range: 0-95 months).</time_frame>
        <population>Intent-to-Treat (ITT) Population: all randomized participants who gave written informed consent. Participants in the ITT population were analyzed according to the treatment arm to which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>5-FU/LV</title>
            <description>Given by one of two regimens. • Mayo Clinic regimen group: LV 20 mg/m^2 IV bolus injection + 5-FU 425 mg/m^2 IV bolus injection daily on Days 1-5 of a four-week cycle, for a total of six cycles (24 weeks), or • Roswell Park regimen group: LV 500 mg/m^2 by two-hour IV infusion + 5-FU 500 mg/m^2 IV bolus injection one hour after the start of the LV infusion on Day 1 of Weeks 1 to 6 of each eight-week cycle, for a total of four cycles (32 weeks)</description>
          </group>
          <group group_id="O2">
            <title>XELOX</title>
            <description>Capecitabine administered as an oral twice daily outpatient intermittent treatment (3-week cycles consisting of two weeks of treatment followed by one week without treatment) combined with intravenous (IV) oxaliplatin on Day 1 of each cycle. Capecitabine was administered orally at a dose of 1000 mg/m^2 twice-daily (equivalent to a total daily dose of 2000 mg/m^2) with the first dose given during the evening of Day 1 and last dose given during the morning of Day 15. Oxaliplatin was administered as a 130 mg/m^2 IV infusion over two hours on Day 1 of each cycle. The XELOX combination was administered for a total of eight cycles (24 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Relapse-Free Survival (RFS) [Time to Event]</title>
          <description>A relapse-free survival (RFS) event included recurrence of the original colon cancer, development of a new colon or rectal cancer, and deaths related to any of the following: treatment, recurrence of the original colon cancer, or development of a new colon or rectal cancer. Participants who had not had any such event at the time of data analysis were censored at the last date they were known to be event-free. Participants whose cause of death was unrelated to treatment or disease recurrence were censored at the time of the last tumor assessment. The median was estimated by the Kaplan-Meier method. The full range values include censored observations.</description>
          <population>Intent-to-Treat (ITT) Population: all randomized participants who gave written informed consent. Participants in the ITT population were analyzed according to the treatment arm to which they were randomized.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="942"/>
                <count group_id="O2" value="944"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="0" upper_limit="95">The median time for RFS was not reached in this adjuvant trial; however, due to a late event in the XELOX arm and an artificial drop in the Kaplan-Meier estimate, an artificial median estimate for the XELOX groups appears.</measurement>
                    <measurement group_id="O2" value="88.6" lower_limit="0" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Descriptive analysis only.</non_inferiority_desc>
            <p_value>0.0015</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>0.91</ci_upper_limit>
            <estimate_desc>The hazard ratio was calculated as XELOX versus 5-FU/LV arms.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival [Number of Events]</title>
        <description>Overall survival was measured as the time from randomization to the date of death, irrespective of the cause of death. Participants who were not reported as having died at the time of the analysis were censored using the date they were last known to be alive.</description>
        <time_frame>Time from randomization date to date of death/date last known to be alive. Median observation time was 83 months (range: 0-95 months).</time_frame>
        <population>Intent-to-Treat (ITT) Population: all randomized participants who gave written informed consent. Participants in the ITT population were analyzed according to the treatment arm to which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>5-FU/LV</title>
            <description>Given by one of two regimens. • Mayo Clinic regimen group: LV 20 mg/m^2 IV bolus injection + 5-FU 425 mg/m^2 IV bolus injection daily on Days 1-5 of a four-week cycle, for a total of six cycles (24 weeks), or • Roswell Park regimen group: LV 500 mg/m^2 by two-hour IV infusion + 5-FU 500 mg/m^2 IV bolus injection one hour after the start of the LV infusion on Day 1 of Weeks 1 to 6 of each eight-week cycle, for a total of four cycles (32 weeks)</description>
          </group>
          <group group_id="O2">
            <title>XELOX</title>
            <description>Capecitabine administered as an oral twice daily outpatient intermittent treatment (3-week cycles consisting of two weeks of treatment followed by one week without treatment) combined with intravenous (IV) oxaliplatin on Day 1 of each cycle. Capecitabine was administered orally at a dose of 1000 mg/m^2 twice-daily (equivalent to a total daily dose of 2000 mg/m^2) with the first dose given during the evening of Day 1 and last dose given during the morning of Day 15. Oxaliplatin was administered as a 130 mg/m^2 IV infusion over two hours on Day 1 of each cycle. The XELOX combination was administered for a total of eight cycles (24 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival [Number of Events]</title>
          <description>Overall survival was measured as the time from randomization to the date of death, irrespective of the cause of death. Participants who were not reported as having died at the time of the analysis were censored using the date they were last known to be alive.</description>
          <population>Intent-to-Treat (ITT) Population: all randomized participants who gave written informed consent. Participants in the ITT population were analyzed according to the treatment arm to which they were randomized.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="942"/>
                <count group_id="O2" value="944"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients With Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="286"/>
                    <measurement group_id="O2" value="242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients Without Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="656"/>
                    <measurement group_id="O2" value="702"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival [Time to Event]</title>
        <description>Overall survival was measured as the time from randomization to the date of death, irrespective of the cause of death. Participants who were not reported as having died at the time of the analysis were censored using the date they were last known to be alive. The median was estimated by the Kaplan-Meier method. The full range values include censored observations.</description>
        <time_frame>Time from randomization date to date of death/date last known to be alive. Median observation time was 83 months (range: 0-95 months).</time_frame>
        <population>Intent-to-Treat (ITT) Population: all randomized participants who gave written informed consent. Participants in the ITT population were analyzed according to the treatment arm to which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>5-FU/LV</title>
            <description>Given by one of two regimens. • Mayo Clinic regimen group: LV 20 mg/m^2 IV bolus injection + 5-FU 425 mg/m^2 IV bolus injection daily on Days 1-5 of a four-week cycle, for a total of six cycles (24 weeks), or • Roswell Park regimen group: LV 500 mg/m^2 by two-hour IV infusion + 5-FU 500 mg/m^2 IV bolus injection one hour after the start of the LV infusion on Day 1 of Weeks 1 to 6 of each eight-week cycle, for a total of four cycles (32 weeks)</description>
          </group>
          <group group_id="O2">
            <title>XELOX</title>
            <description>Capecitabine administered as an oral twice daily outpatient intermittent treatment (3-week cycles consisting of two weeks of treatment followed by one week without treatment) combined with intravenous (IV) oxaliplatin on Day 1 of each cycle. Capecitabine was administered orally at a dose of 1000 mg/m^2 twice-daily (equivalent to a total daily dose of 2000 mg/m^2) with the first dose given during the evening of Day 1 and last dose given during the morning of Day 15. Oxaliplatin was administered as a 130 mg/m^2 IV infusion over two hours on Day 1 of each cycle. The XELOX combination was administered for a total of eight cycles (24 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival [Time to Event]</title>
          <description>Overall survival was measured as the time from randomization to the date of death, irrespective of the cause of death. Participants who were not reported as having died at the time of the analysis were censored using the date they were last known to be alive. The median was estimated by the Kaplan-Meier method. The full range values include censored observations.</description>
          <population>Intent-to-Treat (ITT) Population: all randomized participants who gave written informed consent. Participants in the ITT population were analyzed according to the treatment arm to which they were randomized.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="942"/>
                <count group_id="O2" value="944"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="0" upper_limit="95">The median time to death was not reached in this adjuvant trial.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="0" upper_limit="93">The median time to death was not reached in this adjuvant trial.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Descriptive analysis only.</non_inferiority_desc>
            <p_value>0.0367</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
            <estimate_desc>The hazard ratio was calculated as XELOX versus 5-FU/LV arms.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With at Least One Adverse Event by Most Severe Intensity</title>
        <description>The intensity of all adverse events (AEs) was categorized according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) (version 3.0) grading system. If an AE had occurred which was not contained in the NCI-CTC, a four-point scale (mild, moderate, severe, life-threatening) was used. The terms &quot;severe&quot; and &quot;serious&quot; are not synonymous and are independently assessed for each AE. Only the most severe intensity was counted for multiple occurrences of an AE in one individual. See the AEs results table for details.</description>
        <time_frame>From time of very first drug intake to 28 days after very last drug intake (median [full range] duration of study treatment per arm: 5-FU/LV MAYO CLINIC: 145 [4-208] days; 5-FU/LV ROSWELL PARK: 204 [1-239] days; XELOX: 163 [1-275] days).</time_frame>
        <population>Safety Population: all participants who were randomized and did receive at least one dose of capecitabine, 5-FU, or oxaliplatin. Participants in the safety population were analyzed according to the study treatment they received.</population>
        <group_list>
          <group group_id="O1">
            <title>5-FU/LV MAYO CLINIC</title>
            <description>Mayo Clinic regimen group: LV 20 mg/m^2 IV bolus injection + 5-FU 425 mg/m^2 IV bolus injection daily on Days 1-5 of a four-week cycle, for a total of six cycles (24 weeks)</description>
          </group>
          <group group_id="O2">
            <title>5-FU/LV ROSWELL PARK</title>
            <description>Roswell Park regimen group: LV 500 mg/m^2 by two-hour IV infusion + 5-FU 500 mg/m^2 IV bolus injection one hour after the start of the LV infusion on Day 1 of Weeks 1 to 6 of each eight-week cycle, for a total of four cycles (32 weeks)</description>
          </group>
          <group group_id="O3">
            <title>XELOX</title>
            <description>Capecitabine administered as an oral twice daily outpatient intermittent treatment (3-week cycles consisting of two weeks of treatment followed by one week without treatment) combined with intravenous (IV) oxaliplatin on Day 1 of each cycle. Capecitabine was administered orally at a dose of 1000 mg/m^2 twice-daily (equivalent to a total daily dose of 2000 mg/m^2) with the first dose given during the evening of Day 1 and last dose given during the morning of Day 15. Oxaliplatin was administered as a 130 mg/m^2 IV infusion over two hours on Day 1 of each cycle. The XELOX combination was administered for a total of eight cycles (24 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With at Least One Adverse Event by Most Severe Intensity</title>
          <description>The intensity of all adverse events (AEs) was categorized according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) (version 3.0) grading system. If an AE had occurred which was not contained in the NCI-CTC, a four-point scale (mild, moderate, severe, life-threatening) was used. The terms &quot;severe&quot; and &quot;serious&quot; are not synonymous and are independently assessed for each AE. Only the most severe intensity was counted for multiple occurrences of an AE in one individual. See the AEs results table for details.</description>
          <population>Safety Population: all participants who were randomized and did receive at least one dose of capecitabine, 5-FU, or oxaliplatin. Participants in the safety population were analyzed according to the study treatment they received.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="657"/>
                <count group_id="O2" value="269"/>
                <count group_id="O3" value="938"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mild AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="557"/>
                    <measurement group_id="O2" value="256"/>
                    <measurement group_id="O3" value="855"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="493"/>
                    <measurement group_id="O2" value="217"/>
                    <measurement group_id="O3" value="792"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="299"/>
                    <measurement group_id="O2" value="146"/>
                    <measurement group_id="O3" value="548"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Life-Threatening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From time of very first drug intake to 28 days after very last drug intake (median [full range] duration of study treatment per arm: 5-FU/LV MAYO CLINIC: 145 [4-208] days; 5-FU/LV ROSWELL PARK: 204 [1-239] days; XELOX: 163 [1-275] days).</time_frame>
      <desc>AE reporting is based on the Safety Analysis Population; the patients who were randomized and received at least one dose of capecitabine, 5-FU, or oxaliplatin. Safety Population 5-FU/LV (n = 926); XELOX (n = 938)</desc>
      <group_list>
        <group group_id="E1">
          <title>5-FU/LV MAYO CLINIC</title>
          <description>5-fluorouracil/leucovorin</description>
        </group>
        <group group_id="E2">
          <title>5-FU/LV ROSWELL PARK</title>
          <description>5-fluorouracil/leucovorin</description>
        </group>
        <group group_id="E3">
          <title>XELOX</title>
          <description>Capecitabine in Combination with Intravenous Oxaliplatin (Q3W)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="215" subjects_at_risk="664"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="242" subjects_at_risk="944"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="134" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="208" subjects_at_risk="938"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>FEBRILE NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>COAGULOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>HAEMOLYTIC URAEMIC SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>ANGINA UNSTABLE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA SUPRAVENTRICULAR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK COMPLETE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>PERICARDIAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>VERTIGO POSITIONAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>EYE MOVEMENT DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>STOMATITIS ALL</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>ILEUS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>ENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>SUBILEUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>ABDOMINAL ADHESIONS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>ENTEROCOLITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>GASTRIC HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL TOXICITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>HAEMATEMESIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>ILEITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>INTESTINAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>LARGE INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>NEUTROPENIC COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>ABDOMINAL MASS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>ASCITES</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>CAECITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>COLITIS ISCHAEMIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>COLONIC FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>CROHN’S DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>GASTRITIS EROSIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>ILEUS PARALYTIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>INTERNAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>INTESTINAL PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>MECHANICAL ILEUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL MASS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>PERITONITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>PNEUMATOSIS INTESTINALIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>UPPER GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>GENERAL PHYSICAL HEALTH DETERIORATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>CHEST DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>DISEASE PROGRESSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>HEPATIC LESION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>PORTAL VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>ANAPHYLACTIC REACTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>ANAPHYLACTOID REACTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>NEUTROPENIC SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>ANAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>SEPTIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>ABDOMINAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>ABDOMINAL WALL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>BRONCHOPNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIUM DIFFICILE COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>ENDOPHTHALMITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>HEPATITIS B</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>LOWER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>ORAL CANDIDIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE WOUND INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>SEPSIS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>SKIN INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>ACCIDENTAL OVERDOSE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>INCISIONAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>PROCEDURAL SITE REACTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>SUBDURAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>UPPER LIMB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>WOUND DEHISCENCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ANTICOAGULATION DRUG LEVEL ABOVE THERAPEUTIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>BLOOD BILIRUBIN ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>CULTURE STOOL POSITIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>ANOREXIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>ACIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>DIABETIC KETOACIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>FLUID OVERLOAD</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>HYPONATRAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC DISPLACEMENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>MYOSITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>COLON CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>LOSS OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>CEREBRAL AMYLOID ANGIOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGIC CEREBRAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>HEMIPLEGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC STROKE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>NERVOUS SYSTEM DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>NEUROPATHY PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>PERIPHERAL MOTOR NEUROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>PERIPHERAL SENSORY NEUROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>SCIATICA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>SUPERIOR SAGITTAL SINUS THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>PSYCHOTIC DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>RENAL COLIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>UROGENITAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>MENORRHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>OVARIAN MASS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>VAGINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>DYSAESTHESIA PHARYNX</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>BRONCHOSPASM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>HAEMOPTYSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>LARYNGOSPASM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>PNEUMONIA ASPIRATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>DERMATITIS CONTACT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>THROMBOPHLEBITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>ARTERIAL OCCLUSIVE DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>HYPOVOLAEMIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>JUGULAR VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>NECROSIS OF ARTERY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>SUBCLAVIAN VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>VENA CAVA THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>VENOUS THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="938"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="622" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="262" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="926" subjects_at_risk="938"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="232" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="260" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="167" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="64" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>FEBRILE NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="938"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>LACRIMATION INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="938"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="449" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="219" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="577" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="350" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="190" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="625" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>STOMATITIS ALL</sub_title>
                <counts group_id="E1" subjects_affected="419" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="195" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="142" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="103" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="415" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="118" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="92" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="204" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="187" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="87" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="77" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>FLATULENCE</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>DRY MOUTH</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="938"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="148" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="170" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="332" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="167" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="108" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>TEMPERATURE INTOLERANCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="104" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="938"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="938"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ANOREXIA</sub_title>
                <counts group_id="E1" subjects_affected="101" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="240" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="68" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="938"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="117" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>PAIN IN JAW</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="938"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>PARAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="339" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>NEUROPATHY PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="279" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>DYSGEUSIA</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="126" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="103" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="99" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>PERIPHERAL SENSORY NEUROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="152" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>DYSAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="104" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>LETHARGY</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>HYPOAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="59" subjects_at_risk="938"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="78" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="938"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="63" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>DYSAESTHESIA PHARYNX</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="93" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>RHINORRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="938"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="278" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" subjects_affected="159" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="84" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>DRY SKIN</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="938"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="938"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffmann-La Roche</organization>
      <phone>800-821-8590</phone>
      <email>genentech@druginfo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

